Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

38 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-20

Study Completion Date

2023-09-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phase 1b/2 study to evaluate the FGFRi futibatinib in combination with the MEKi binimetinib in patients with advanced KRASmt tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

NCT05945823

Siewert Type 1 GEJ Cancer Pancreatic Cancer Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer +2 more

ACTIVE_NOT_RECRUITING PHASE2

A Study of TAS-120 in Patients With Advanced Solid Tumors

NCT02052778

Cholangiocarcinoma Urothelial Cancer Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors +3 more

COMPLETED PHASE1/PHASE2

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

NCT05364073

Non-Small Cell Lung Cancer (NSCLC) Metastatic Non-Small Cell Lung Cancer Advanced Non-Small Cell Lung Cancer +3 more

ACTIVE_NOT_RECRUITING PHASE1

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

NCT04699968

Non-Small-Cell Lung Cancer

WITHDRAWN PHASE2

A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC

NCT03904823

EGFR-mutant Non-Small Cell Lung Cancer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open-label, nonrandomized, uncontrolled Phase 1b/2 study to determine the recommended phase 2 dose (RP2D) of futibatinib in combination with binimetinib and to explore the preliminary antitumor activity of futibatinib in combination with binimetinib in patients with advanced KRASmt tumors.

The study will consist of two parts:

* Part 1: Dose-Escalation part to determine the RP2D and dosing schedule of futibatinib in combination with binimetinib in patients with advanced cancer disease
* Part 2: Dose-Expansion part to evaluate the preliminary antitumor activity of futibatinib in combination with binimetinib at the RP2D in patients with advanced KRASmt NSCLC

Patients will receive study treatment until progressive disease or any other discontinuation or withdrawal criterion is met.

No patients were enrolled in Phase 2 as the Sponsor decided to not proceed with the dose expansion Phase 2 part of the TAS-120-204 study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations Non-Small Cell Lung Cancer KRAS Gene Mutation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Futibitanib in combination with binimetinib

Dose escalation: Futibitanib in combination with binimetinib in patients with advanced cancer disease.

Dose expansion: Futibatinib in combination with binimetinib at the RP2D in patients with advanced KRASmt NSCLC

Group Type EXPERIMENTAL

Futibatinib and Binimetinib

Intervention Type DRUG

Patients will receive futibatinib once daily in combination with binimetinib twice daily by oral administration on a 21-day cycle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Futibatinib and Binimetinib

Patients will receive futibatinib once daily in combination with binimetinib twice daily by oral administration on a 21-day cycle

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed advanced cancer of any tumor type (Part 1) or NSCLC with a confirmed KRAS mutation as determined by local results (Part 2)
* Appropriate candidate for experimental therapy
* For patients in Part 2 only: Patient has radiographically measurable disease per RECIST 1.1 criteria.
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
* Adequate cardiac function (Left ventricular ejection fraction (LVEF) ≥50% )
* Adequate organ function
* Must have tumor tissue specimen available (optional for patients in Part 1)

Exclusion Criteria

* History or current evidence of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues
* Current evidence or history of clinically significant corneal or retinal disorder as confirmed by ophthalmologic examination.
* Known untreated central nervous system (CNS) metastases or history of uncontrolled seizures.
* Significant gastrointestinal disorder(s) that could interfere with absorption of futibatinib/binimetinib
* Patients who have neuromuscular disorders that are associated with elevated creatinine kinase (CK)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No